22nd Century Group (XXII) 2019年年度报告「NYSE」.pdf

1、2019 ANNUAL REPORTexciting start to a novel process in the world of hemp/cannabis plant genetics that is expected to yield valuable,new,proprietary hemp/cannabis plants and intellectual property for 22nd Century.To complement our hemp/cannabis plant research,we have implemented a strategy to develop

2、 strategic partnerships to generate profitable revenue in the legal,hemp-derived CBD products space and to commercialize our proprietary plants and intellectual property in development.Our first partnership was formed last year with Panacea Life Sciences(Panacea),a vertically integrated company loca

3、ted in Golden,Colorado.We look forward to Panaceas continued growth as they focus on their branded,legal,hemp CBD products business.We believe 22nd Centurys leadership position in the legal hemp/cannabis space will be well-supported by the marketplace differentiation resulting from the commercializa

4、tion of our proprietary,unique and valuable hemp/cannabis plants and intellectual property through our strategic partnerships.In conclusion,we continue to advance our reduced nicotine tobacco plant science,intellectual property and commercialization strategies,and we look forward to a positive decis

5、ion from FDA authorizing the launch of our VLN reduced nicotine tobacco cigarettes in the U.S.with our requested claims.We also continue to execute our hemp/cannabis strategies to leverage our scientific and commercial assets and capabilities to further establish our leadership position in the emerg

6、ing,fast-growing and legal hemp/cannabis space.We thank you for your continued interest in and support of 22nd Century and the important work we are doing to improve and enhance quality of life through innovative and leading plant science.Letter to ShareholdersDear Fellow Shareholders,Michael J.Zerc